Fain, Olivier http://orcid.org/0000-0002-1974-3870
Du-Thanh, Aurelie
Gobert, Delphine
Launay, David
Inhaber, Neil
Boudjemia, Karima
Aubineau, Magali
Sobel, Alain
Boccon-Gibod, Isabelle
Weiss, Laurence
Bouillet, Laurence
Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Received: 23 July 2021
Accepted: 3 March 2022
First Online: 1 April 2022
Declarations
:
: Not applicable: in line with local regulations, neither approval from a local ethics committee nor written informed consent were required. However, the ATU protocol was subject to approval by the ANSM before initiation. Also, before seeking treatment access, physicians obtained verbal consent from each patient for treatment with lanadelumab, which could be done via telephone.
: Not applicable.
: OF is a consultant for BioCryst, CSL Behring, and Takeda. AD has received travel grants from Novartis and Takeda and has participated on advisory boards for Takeda, and her institute has received partial research funding from Novartis. DG has received honoraria and travel grants from Pharming and Takeda.DL has received honoraria and research funding from CSL Behring and Takeda. NI is an employee of and holds stock/stock options in Takeda. KB is a former employee of and holds stock/stock options in Takeda; her current affiliation is Medical Director at Vifor Pharma. MA has received honoraria and travel grants from Takeda. IB and LB have received honoraria and travel grants from CSL Behring, Novartis, Pharming, and Takeda, and their institute has received research funding from BioCryst, CSL Behring, Novartis, and Takeda. AS and LW have no relevant competing interest to disclose.